Latest Zoledronic acid Stories
EAST HANOVER, N.J., Dec.
SILVER SPRING, Md., Nov. 19, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone.
THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S.
THOUSAND OAKS, Calif., Nov.
EAST HANOVER, N.J., Oct.
Labeling change adds warning about possible risks of long-term use of osteoporosis drugs SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ -- The U.S.
THOUSAND OAKS, Calif., Oct.
A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs â€“ when used long term â€“ may be related to unusual but serious fractures of the thigh bone.
EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of ZometaÂ® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1).
THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus ZometaÂ® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases.